Active substances
Insulin lispro + Insulin protamine
- SFDA 8
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| HUMALOG KWIK-PEN MIX 25 | 25,75 %,% | Suspension for injection · Subcutaneous use | 5 Pre-filled pen | SAR 161.30 | Biological · Prescription | ELI LILLY NEDERLAND B.V. | Valid |
| HUMALOG KWIK-PEN MIX 50 | 50,50 IU/ml,IU/ml | Suspension for injection · Subcutaneous use | 5 Pre-filled pen | SAR 161.30 | Biological · Prescription | ELI LILLY NEDERLAND B.V. | Valid |
| HUMALOG KWIK-PEN MIX 25 | 25, 75 IU/ml | Suspension for injection · Subcutaneous use | 5 Pre-filled pen | SAR 167.95 | Biological · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| HUMALOG KWIK-PEN MIX 50 SUSPEMSION FOR INJECTION | 50, 50 IU/ml | Suspension for injection · Subcutaneous use | 5 Pre-filled pen | SAR 167.95 | Biological · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| HUMALOG MIX 25 CATRIDGE | 25, 75 IU/ml | Suspension for injection · Subcutaneous use | 5 Cartridge | SAR 145.25 | Biological · Prescription | ELI LILLY NEDERLAND B.V. | Withdrawn by MAH · Not Marketed |
| HUMALOG MIX 25 CATRIDGE | 25, 75 IU/ml | Suspension for injection · Subcutaneous use | 5 Cartridge | SAR 168.60 | Biological · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| HUMALOG MIX 50 CATRIDGE | 50, 50 IU/ml | Suspension for injection · Subcutaneous use | 5 Cartridge | SAR 145.25 | Biological · Prescription | ELI LILLY NEDERLAND B.V. | Withdrawn by MAH · Not Marketed |
| HUMALOG MIX 50 CATRIDGE | 50, 50 IU/ml | Suspension for injection · Subcutaneous use | 5 Cartridge | SAR 145.25 | Biological · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
DIABETES MELLITUS TYPE 1; DIABETES MELLITUS TYPE 2
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.